The Role of Immunohistochemistry in Discriminating Primary From Secondary Extramammary Paget Disease
- 1 April 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Dermatopathology
- Vol. 32 (2), 137-143
- https://doi.org/10.1097/dad.0b013e3181b71481
Abstract
Extramammary Paget disease (EMPD) is categorized into 2 groups: primary EMPD or EMPD secondary to underlying malignancy. Primary EMPD has a better prognosis, and the ability to distinguish between the 2 subsets has clinical relevance. Recent studies have suggested that immunostains, including cytokeratin (CK) 7, CK20, and BRST-2, distinguish between the 2 groups. We analyzed a large series of EMPD with an expanded immunohistochemical panel to assess its value in distinguishing primary from secondary disease.Formalin-fixed, paraffin-embedded sections of 98 EMPD specimens from 61 patients (45 primary and 16 secondary) were immunostained with CK7, CK20, HER-2/neu, BRST-2, CDX2, androgen receptor (AR), and cyclin D1. The study included 44 women and 17 men (median age: 73 years). Median follow-up time was 47 months.All EMPD specimens were vibrantly positive for CK7. The frequency of positivity for all EMPD samples was CK20 (28%), BRST-2 (40%), HER-2/neu (64%), CDX2 (10%), AR (16%), and cyclin D1 (76%). For primary EMPD, the frequency of positivity was CK20 (22%), BRST-2 (48%), HER-2/neu (65%), CDX2 (2%), AR (21%), and cyclin D1 (84%). For secondary EMPD, the frequency of positivity was CK20 (50%), BRST-2 (25%), HER-2/neu (60%), CDX2 (33%), AR (0%), and cyclin D1 (53%). Notably, all 6 of 7 cases of EMPD secondary to an anorectal adenocarcinoma tested were HER-2/neu negative and 5 of those 6 cases (80%) were CDX2 positive.The role of CK7, CK20, and BRST-2 in distinguishing primary and secondary EMPD is limited because CK20 and BRST-2 were positive in large subsets of both groups. An expanded immunohistochemical panel, including HER-2/neu and CDX2, may be useful in discriminating primary EMPD from EMPD secondary to anorectal adenocarcinoma but fails to distinguish primary EMPD from EMPD secondary to urothelial or prostatic malignancy. The consistent overexpression of HER-2/neu in primary EMPD suggests a role for trastuzumab therapy in patients with recurrent disease.Keywords
This publication has 29 references indexed in Scilit:
- Extramammary Paget's disease of the groin with underlying carcinoma and fatal outcomeClinical and Experimental Dermatology, 2008
- Concordant over‐expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget's diseaseInternational Journal of Dermatology, 2008
- Expression and prognostic significance of Stat5a and E‐cadherin in extramammary Paget’s diseaseJournal of Cutaneous Pathology, 2006
- HER-2 Gene Amplification in Paget Disease of the Nipple and Extramammary Site: A Chromogenic In Situ Hybridization StudyDiagnostic Molecular Pathology, 2006
- Expression of cytokeratin subtypes in intraepidermal malignancies: a guide for differentiationJournal of Cutaneous Pathology, 2006
- Expression of phosphorylated Stat3, cyclin D1 and Bcl-xL in extramammary Paget diseaseBritish Journal of Dermatology, 2005
- LYMPHOVASCULAR AND MARGINAL INVASION AS USEFUL PROGNOSTIC INDICATORS AND THE ROLE OF c-erbB-2 IN PATIENTS WITH MALE EXTRAMAMMARY PAGET'S DISEASE: A STUDY OF 31 PATIENTSJournal of Urology, 2005
- HER-2/neu expression in Paget disease of the vulva and the female breastGynecologic Oncology, 2004
- Mammary and extramammary Paget's diseaseJournal of Clinical Pathology, 2000
- Extramammary Paget's disease: Prognosis and relationship to internal malignancyJournal of the American Academy of Dermatology, 1985